News

Filter

1 to 9 of 106 results

Russia may face shortage of anti-AIDS drugs in 2015

Russia may face shortage of anti-AIDS drugs in 2015

28-01-2015

Russia may face with a shortage of anti-AIDS drugs in 2015 due to the current complex situation in the…

Anti-viralsHealthcareMarkets & MarketingPharmaceuticalRussia

Merck & Co drops marketing of hepatitis C drug Victrelis in USA

Merck & Co drops marketing of hepatitis C drug Victrelis in USA

22-01-2015

In an open letter to pharmacy professions, US pharma giant Merck & Co has advised that it is voluntarily…

Anti-viralsMarkets & MarketingMerck & CoPharmaceuticalUSAVictrelis

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

Advantages of Gilead’s Harvoni over emerging hepatitis C treatments

10-11-2014

US surveyed specialists anticipate prescribing Gilead Sciences’ Harvoni to a high proportion of their…

Anti-viralsBiotechnologyGilead SciencesHarvoniJanssenMarkets & MarketingMedivirOlysioSovaldiUSA

Bristol-Myers reveals access plan for hep C drug daclatasvir

03-11-2014

US Pharma major Bristol-Myers Squibb has recently revealed a commercial strategy for sales of its new…

Anti-viralsBristol-Myers SquibbdaclatasvirDaklinzaMarkets & MarketingPharmaceuticalPricing

Mylan debuts generic Viramune XR in USA

Mylan debuts generic Viramune XR in USA

31-10-2014

US generic drugmaker Mylan said yesterday that it has launched its nevirapine extended-release tablets,…

Anti-viralsBoehringer IngelheimGenericsMarkets & MarketingMylanUSAViramune

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

Harvoni will keep Gilead atop hepatitis C treatment landscape, says analyst

23-10-2014

The recent US Food and Drug Administration approval of Harvoni (ledipasvir/sofosbuvir), Gilead Sciences’…

Anti-viralsBiotechnologyGilead SciencesHarvoniMarkets & MarketingPricingSovaldiUSA

Gilead looks set to stay ahead of the pack in HIV treatment market

Gilead looks set to stay ahead of the pack in HIV treatment market

09-10-2014

US biotech major Gilead Sciences’ announcement of positive Phase III results for its investigational…

Anti-viralsBiotechnologycobicistatelvitegravirEmtricitabine and Tenofovir Disoproxil FumaraGilead SciencesMarkets & MarketingResearchTriumeqUSAViiV Healthcare

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

Bristol-Myers Squibb pulls NDA for combo hep C drug asunaprevir

08-10-2014

Bristol-Myers Squibb has decided that it will not pursue US Food and Drug Administration approval of…

Anti-viralsasunaprevirBristol-Myers SquibbdaclatasvirGenotypeGilead SciencesMarkets & MarketingPharmaceuticalRegulationSovaldiUnited StatesUS Food and Drug AdministrationUSA

1 to 9 of 106 results

COMPANY SPOTLIGHT

Menarini

Back to top